the introduction and evaluation of fit · 2ww criteria or high risk confirmed ida (men and...

33
The introduction and evaluation of FIT James Turvill September 2019

Upload: others

Post on 20-Jan-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

The introduction and evaluation of FIT

James Turvill

September 2019

Page 2: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Faecal Immunochemical Test for haemoglobin

• FIT

– BCSP

• Asymptomatic screening

• 60-74years

• Cut-off 120µg Hb/g faeces

– 2ww patients for suspected colorectal cancer

• Research

– Patients at low risk for colorectal cancer

• NICE DG30

Page 3: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Faecal Immunochemical Test for haemoglobin

• FIT

– BCSP

• Asymptomatic screening

• 60-74years

• Cut-off 120µg Hb/g faeces

– 2ww patients for suspected colorectal cancer

• Research

– Patients at low risk for colorectal cancer

• NICE DG30

Page 4: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Indications for use of FIT in DG30 People: • without rectal bleeding • who have unexplained symptoms that do not meet the

criteria for a suspected cancer pathway

REPLACES

People: • >50yrs with unexplained

– abdominal pain – weight loss

• <60yrs with – changes in their bowel habit – iron-deficiency anaemia

• >60yrs with anaemia even in the absence of iron deficiency

Page 5: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Faecal Calprotectin IBS v IBD

•use in adults

•new lower gastrointestinal

symptoms

•cancer is not suspected

•NICE DG11

Page 6: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets
Page 7: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

YFCCP economic evaluation

• Health economic evaluation with YHEC

• Outcome data compared against historic standard care, predicted outcomes from FC usage and outcomes from this implementation using standard cut off (per 1000 pts)

Intervention No FC (ESR + CRP) Incremental

Total costs £308,954 £416,839 -£107,885

Correctly diagnosed IBS cases 849 677 172

Correctly diagnosed IBD cases 66 25 41

Unnecessary colonoscopies (i.e. false +ves) 79 251 -172

Intervention Standard cut-off Incremental

Total costs £308,954 £467,820 -£158,866

Correctly diagnosed IBS cases 849 562 287

Correctly diagnosed IBD cases 66 68 -1

Unnecessary colonoscopies (i.e. false +ves) 79 366 -287

Page 8: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

YFCCP economic evaluation

• Health economic evaluation with YHEC

• Outcome data compared against historic standard care, predicted outcomes from FC usage and outcomes from this implementation using standard cut off (per 1000 pts)

Intervention No FC (ESR + CRP) Incremental

Total costs £308,954 £416,839 -£107,885

Correctly diagnosed IBS cases 849 677 172

Correctly diagnosed IBD cases 66 25 41

Unnecessary colonoscopies (i.e. false +ves) 79 251 -172

Intervention Standard cut-off Incremental

Total costs £308,954 £467,820 -£158,866

Correctly diagnosed IBS cases 849 562 287

Correctly diagnosed IBD cases 66 68 -1

Unnecessary colonoscopies (i.e. false +ves) 79 366 -287

Page 9: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT NICE DG30:

FIT for low risk patients

How does it fit with FC?

Page 10: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT NICE DG30:

FIT for low risk patients

Page 11: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT NICE DG30:

FIT for low risk patients

?

Page 12: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT or FC?

Page 13: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT or FC?

Page 14: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Roll out of FIT: the challenges • Introduce FIT

• Evaluate FIT

• Compare the effectiveness of FC and FIT

≥60years not high risk for CRC (2ww)

abdominal pain

weight loss

anaemia in the absence of iron deficiency

FIT

18-59years FC v FIT

YFCCP + FIT

not high risk for CRC (2ww)

baseline investigations normal

diagnostic uncertainty

not isolated rectal bleeding

FC and FIT

Page 15: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Diagnostic accuracy study: 1

• Patient presents with possible lower gastrointestinal disease

• Baseline assessment and investigations as appropriate – FBC, CRP, ferritin, TFT, coeliac screen

– Stool culture, C.difficile toxin

• Not 2ww for cancer

• Diagnostic uncertainty

• Not isolated rectal bleeding: surgical referral

Page 16: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Only Calprotectin available to request

Question to prompt GP to request FIT

If you say “No” – nothing happens and you just get the calprotectin

If you say “Yes” FIT auto requested

This “Help” prompt appears to help ensure FIT test not performed if rectal bleeding or 2WW met

Patient 18-59yrs

Page 17: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

YFCCP requests & referrals

Page 18: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

YFCCP Prevalence of disease

Prevalence of organic colonic disease: IBD, significant polyps and colorectal cancer by age and referral/endoscopic pathway.

Page 19: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Patient ≥60yrs Both tests available to request if needed Choose an option in order to proceed….

FIT test selected - this pop-up box appears

One of the top three options selected This pop-up box then appears

Calprotectin cannot be co-requested with FIT

Page 20: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Diagnostic accuracy study: 2 • 18-59 years: option to request FC

– ICE will ask then you to request FIT

• ≥60 years: option to request FIT – Specific indications for referral

• Patient pack – Information sheet – Patient questionnaire – Consent form – FIT picker – Instructions for use – SAE

• Universal container (blue top) • Conventional (safety netted) follow up with results

Page 21: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FC needs a universal pot

Page 22: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT needs a picker

Page 23: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT needs a picker

What the patient needs to do: Name

Date of birth Date of sampling

Page 24: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Diagnostic accuracy study 3 ≥60 years: • FIT positive: 2ww colorectal referral • FIT negative: reassure colorectal cancer very unlikely

– treat symptomatically and review – routine referral or consider uro-gynaecological disease

18-59 years: • follow the YFCCP • FC <100: IBS likely • FC ≥100: repeat

– repeat <100: IBS likely – repeat FC 100-250: routine gastroenterology referral – repeat FC >250: STT colonoscopy/urgent gastroenterology referral

IF FC <250 ON COMPLETION OF YFCCP BUT ANY FIT IS POSITIVE:

2WW COLORECTAL REFERRAL

Page 25: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets
Page 26: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT+ve: 2WW

Page 27: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT+ve: 2WW

FIT+ve: 2WW

Page 28: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

FIT+ve: 2WW

FIT+ve: 2WW

FIT+ve: 2WW

Page 29: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Diagnostic accuracy study: 4

• GP management/referral guidance will be provided by the laboratory to accompany the FC/FIT result

• GP information sheet

• Training video

• ‘FIT positive indication for referral’ will be added to the 2ww for suspected colorectal proforma

• Safety netting

• Data collection

Page 30: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Expected outcomes • ≥60 years:

– numbers? – FIT positive: 10% – significant disease: 50%

• 18-59 years: – numbers?

• current YFCCP requests: 4000/year • FC requests as a proportion of referrals: 15%

– FC positive: 15% • FC>250 significant disease: 50%

– FIT positive and FC negative: 5% • significant disease: 60%

– numbers needed to diagnose significant disease • YFCCP: 3.8 • No YFCCP: 6.8

– FC/FIT negative: follow the YFCCP • reassure, treat and review

Page 31: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Thank you

Any queries, contact me:

[email protected]

01904 725480

Questions?

Page 32: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

• New or persistent lower GI symptoms or abdominal pain for > 3 weeks

• Unexplained weight loss

• Rectal bleeding

2WW Criteria or

High risk confirmed IDA (Men and non-menstruating women >40y, women >50y)

Non-2WW

>50Y <50Y

2WW Referral Positive Fit

Negative Fit

Possible IBD/ IBS

Rectal

Bleeding

alone

>250

Offer faecal

calprotectin test

Repeat after 4

weeks if 100 -250

Likely IBS

Manage in

Primary

Care

<100

100-250

Urgent

not 2WW

referral

Offer FIT consider CT if

weight loss sx

Safety netting in primary care

Consider advice and guidance or

routine referral for persistent or

troublesome symptoms

Northern Cancer Alliance Colorectal Symptoms Assessment Pathway

Routine

GI

referral

Unexplained confirmed medium risk IDA or clinical suspicion of colorectal cancer

2x Platelets >450

6 weeks apart

Page 33: The introduction and evaluation of FIT · 2WW Criteria or High risk confirmed IDA (Men and non-menstruating women >40y, women >50y) Non-2WW >50Y 2x Platelets

Integrated Lower GI Pathway

33

Provid

er Allianc

e

Population

health managem

ent

HIGH RISK

Colorectal Cancer Fulfils NICE

Guidance (NG12)

LOW RISK

Colorectal Cancer Does not fulfil NICE Guidance (NG12)

2WW

Perform FIT test along with sending 2ww referral Age

≥50

Age <50

These patients fulfil low risk NICE guidance (DG30)

Perform FIT Test

FIT +ve

FIT -ve

2WW Reassure, follow up as required Consider FCP

NICE Guidance DG11

Worrying Symptoms

Reassure and Consider performing FCP

Fulfi ls NICE guidance (DG11)

FC <100

FC ≥ 100

Primary Care

Management and Review

Repeat FCP

FC <100

FC >250

Routine Gastro

Referral

Urgent Gastro

Referral

Lower GI Symptoms

Age ≤50 with fresh rectal bleeding, no

other symptoms

Refer for Flexi Sigmoidoscopy

FC 100-250

IBS Pathway